Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
11 oct. 2023 09h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two...
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
09 oct. 2023 08h15 HE
|
AnaptysBio, Inc.
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering...
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
09 oct. 2023 08h00 HE
|
AnaptysBio, Inc.
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo...
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
18 sept. 2023 16h15 HE
|
AnaptysBio, Inc.
After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023...
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
12 sept. 2023 09h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
07 août 2023 16h15 HE
|
AnaptysBio, Inc.
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023Initiating a global Phase 2b trial for...
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
31 juil. 2023 13h34 HE
|
AnaptysBio, Inc.
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...
AnaptysBio Announces Participation in Upcoming Investor Conferences
30 mai 2023 16h15 HE
|
AnaptysBio, Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
11 mai 2023 16h15 HE
|
AnaptysBio, Inc.
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for...
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
02 mai 2023 09h15 HE
|
AnaptysBio, Inc.
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab...